BMS 182657

a dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme; structure given in first source

Also Known As:

2,3,4,5-tetrahydro-3-((2-mercapto-1-oxo-3-phenylpropyl)amino)-2-oxo-1H-benzazepine-1-acetic acid; BMS-182657

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Hypertension (High Blood Pressure) 11/01/1995 - "Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure."
2.	Heart Failure 11/01/1995 - "Hence, BMS-182657 is a dual inhibitor of NEP and ACE, is antihypertensive irrespective of the activity of the renin-angiotensin system and has acute hemodynamic effects in hamsters with heart failure greater than those produced by selective inhibition of NEP or ACE. " 11/01/1995 - "Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure."

1.	Neprilysin (Neutral Endopeptidase)
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.	Antihypertensive Agents (Antihypertensives)